<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969227</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001690</org_study_id>
    <nct_id>NCT01969227</nct_id>
  </id_info>
  <brief_title>The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures</brief_title>
  <official_title>The Effects of Subanesthetic Ketamine on Respiratory Stimulation and Transpulmonary Pressures in Mechanically Ventilated Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maintaining the patency of upper airway in sedated and anesthetized patients is challenging
      especially when patients are ready to be weaned from mechanical ventilation. Impairment of
      airway patency is a common cause of extubation failure and opioids and hypnotics can
      adversely affect airway patency.

      Ketamine, a noncompetitive antagonist of N-methyl-D- aspartate (NMDA), unlike other
      anesthetics activates respiratory effort and promotes bronchodilation. At subanesthetic
      plasma concentration, ketamine reduces both opioid and propofol requirements. Recent animal
      data suggests that when added to propofol in a sedation regimen, ketamine decreased
      hypoventilation when compared to propofol alone because ketamine can increase genioglossus
      phasic activity while abolishing the coupling between loss of consciousness and upper airway
      dilator muscle activity. However, this relationship has not been examined in human in
      combination of other drugs.

      The purpose of this pharmaco-physiological interaction trial is to evaluate the effects of
      ketamine on breathing and electroencephalography in mechanical ventilated patients.
      Spirometry will be utilized to evaluate upper airway patency. Polysomnography (PSG- Alice
      PDx) will be used to evaluate the effects of ketamine on EEG during wakefulness and sleep. An
      esophageal balloon will be inserted to measure esophageal pressure, which enables us to
      measure the effects of ketamine on transpulmonary pressure. A volumetric capnography, NICO
      noninvasive device from Respironics will be used to measure anatomical dead space, CO2
      production, mean expiratory CO2 and slope of the alveolar plateau of the volumetric capnogram
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak inspiratory flow</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tidal volume</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duty cycle</measure>
    <time_frame>8 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minute ventilation</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transpulmonary pressure</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressure</condition>
  <arm_group>
    <arm_group_label>subanesthetic ketamine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subanesthetic ketamine</intervention_name>
    <arm_group_label>subanesthetic ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years admitted to ICU requiring mechanical ventilation

          -  Suitable for spontaneous breathing trial

          -  Candidate to received low dose ketamine by the primary critical care team

        Exclusion Criteria:

          -  Esophageal injury

          -  Allergic to ketamine

          -  Known neurodegenerative disorders

          -  Major neurologic disorders (elevated ICP)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Eikermann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Eikermann, MD. PhD</last_name>
    <email>meikermann@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hsin Lin, PharmD</last_name>
    <email>hlin13@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Eikermann, MD, PhD</last_name>
      <phone>617-643-4408</phone>
      <email>meikermann@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Hsin Lin, PharmD</last_name>
      <email>hlin13@partners.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Eikermann M, Grosse-Sundrup M, Zaremba S, Henry ME, Bittner EA, Hoffmann U, Chamberlin NL. Ketamine activates breathing and abolishes the coupling between loss of consciousness and upper airway dilator muscle dysfunction. Anesthesiology. 2012 Jan;116(1):35-46. doi: 10.1097/ALN.0b013e31823d010a.</citation>
    <PMID>22108392</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Matthias Eikermann</investigator_full_name>
    <investigator_title>Director of Research, Surgical Intensive Care Unit</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

